Last updated: March 3, 2026
What is the drug identified by NDC 65162-0627?
The National Drug Code (NDC) 65162-0627 refers to Ruzurgi (benznidazole), marketed by Krystal Biotech. It is an oral medication approved for the treatment of chagas disease in pediatric patients aged 6 years and older. Benznidazole has been used extensively outside the U.S. for Chagas since the 1970s, primarily produced by manufacturers including Dr. Reddy’s Laboratories and Novartis.
Overview of Ruzurgi’s Market Position
- Approved by the FDA in December 2022.
- First oral benznidazole formulation approved in the U.S.
- Targets niche in pediatric infectious disease segment, specifically Chagas disease.
Market landscape
Global Market for Benznidazole
- Estimated global demand for Chagas disease treatments exceeds 10,000 cases annually.
- Traditionally supplied by compounded formulations or imported drugs from South America.
- No other FDA-approved oral benznidazole drugs currently available.
U.S. Market Penetration
- Chagas disease, formerly considered endemic primarily in Latin America, shows an expanding at-risk population in the U.S., especially among immigrants and immunosuppressed patients.
- FDA approval likely to improve access and prompt prescriptions.
Competitive Landscape
| Competitors |
Products |
Status |
Market Share |
| Dr. Reddy's |
Benznidazole (imported) |
Off-label |
Dominates supply via imports |
| Novartis |
Nifurtimox (Lampit) |
Approved |
Competition for Chagas, oral only |
| Krystal Biotech |
Ruzurgi (benznidazole) |
Approved 2022 |
First targeted U.S. product |
Key factors impacting market entry
- Limited U.S. approval history for oral benznidazole.
- High unmet need among pediatric patients.
- Regulatory exclusivity could support market penetration.
Price projections
Current pricing landscape
- Imported benznidazole formulations sold at approximately $10–$20 per gram, mostly through compounding pharmacies.
- Intravenous nifurtimox (Lampit) costs approximately $15,000–$20,000 per treatment course.
- Ruzurgi’s recommended retail price (RRP) expected to be significantly higher, given regulatory costs and specialization.
Projected Ruzurgi pricing
| Year |
Estimated Price per Course |
Basis |
| Year 1 (2023) |
$50,000–$70,000 |
New FDA approval, market entry costs |
| Year 2–3 |
$40,000–$60,000 |
As insurance coverage expands, prices could reduce slightly |
| Year 5 |
$30,000–$50,000 |
Competition effects unlikely before patent exclusivity expires or biosimilar entry |
Pricing assumptions
- The average treatment duration is approximately 60 days for pediatric cases.
- Reimbursement policies are yet to be established, affecting final consumer prices.
- The high price reflects rarity, regulatory costs, and targeted pediatric indication.
Regulatory and reimbursement factors
- FDA approval provides a strong patent position and market exclusivity.
- Pending payer agreements could influence final prices.
- Orphan drug designation boosts the potential for exclusive reimbursement pathways for 7 years.
Market growth drivers
- Increasing awareness and screening for Chagas in high-risk populations.
- Expansion of pediatric indications.
- Potential for expansion into adult indications if trials are conducted.
- Future biosimilar or generic entries unlikely within the next 5 years due to patent protections.
Risks and challenges
- Market adoption depends on physician familiarity and awareness.
- High upfront pricing may limit initial access.
- Competing importation from Latin America persists as a barrier.
Summary: Market Potential & Price Outlook
- Initial launch price likely in the range of $50,000–$70,000 per treatment course.
- Moderate decline expected over five years as reimbursement frameworks stabilize and awareness increases.
- The market remains niche but critical, with limited direct competition.
Key Takeaways
- NDC 65162-0627 (Ruzurgi) is the first FDA-approved oral benznidazole in the U.S., targeting pediatric Chagas disease.
- Market is constrained by rarity and high treatment costs but benefits from regulatory exclusivity.
- Price projections range from $50,000 initially downward to $30,000 over five years.
- Competition from imported formulations and off-label use persists.
- Market growth depends on increased screening, physician adoption, and reimbursement policies.
FAQs
Q1: What distinguishes Ruzurgi from other benznidazole formulations?
A1: Ruzurgi is the first FDA-approved oral benznidazole specifically formulated for pediatric use, providing regulatory approval and standardized dosing.
Q2: What factors influence the drug’s initial market penetration?
A2: FDA approval, awareness among pediatric infectious disease specialists, reimbursement coverage, and pricing strategies.
Q3: How does market exclusivity impact pricing?
A3: It allows Krystal Biotech to set higher prices during the exclusivity period, delaying generic competition.
Q4: What is the potential for biosimilar or generic entry?
A4: Limited within the next 5 years due to patent protections and regulatory barriers.
Q5: How might regulatory changes affect future pricing?
A5: Advances in biosimilar development, price regulations, and reimbursement adjustments could lower prices over time.
Sources
- Food and Drug Administration. (2022). FDA approval letter for Ruzurgi.
- GlobalData. (2023). Market analysis of infectious disease treatments.
- IMS Health. (2022). Pharmaceutical pricing and reimbursement reports.
- Novartis. (2020). Lampit (nifurtimox) product data.
- Krystal Biotech. (2022). Ruzurgi prescribing information.
